Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02135965 · ClinicalTrials.gov registry record · Early Phase 1
Testing Potential Synergistic Effects of Albuterol and Caffeine on Metabolic Rate
A Early Phase 1 study of Healthy Volunteers, sponsored by Pennington Biomedical Research Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT02135965 is a Early Phase 1 study of Healthy Volunteers that has completed, run by Pennington Biomedical Research Center. The registered enrollment target is 8 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02135965, a Early Phase 1 study of Healthy Volunteers, has completed, sponsored by Pennington Biomedical Research Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to define a ratio of Caffeine and albuterol that gives a synergistic increase in metabolic rate.
Conditions Studied
Interventions
- DRUG 2mg of Albuterol
- DRUG 4mg of Albuterol
- DRUG 100mg of Caffeine
- DRUG 200mg of Caffeine
- DRUG Albuterol 2mg & Caffeine 100mg
Study Locations (1)
Louisiana
- Pennington Biomedical Research Center - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2009-04 |
| Est. Completion | 2011-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02135965
The ClinicalTrials.gov registry entry for NCT02135965 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (98% lower). The listed sponsor is Pennington Biomedical Research Center, which has 258 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 5 interventions - of which 2mg of Albuterol is the first listed.
NCT02135965 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT02135965 about?
NCT02135965 is a clinical study titled "Testing Potential Synergistic Effects of Albuterol and Caffeine on Metabolic Rate". The purpose of this study is to define a ratio of Caffeine and albuterol that gives a synergistic increase in metabolic rate.
What is the current status of trial NCT02135965?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2009-04. Estimated completion is 2011-08.
What conditions does trial NCT02135965 study?
This clinical trial studies the following conditions: Healthy Volunteers.
What interventions are being tested in trial NCT02135965?
The interventions under investigation include: 2mg of Albuterol (DRUG), 4mg of Albuterol (DRUG), 100mg of Caffeine (DRUG), 200mg of Caffeine (DRUG), Albuterol 2mg & Caffeine 100mg (DRUG).
Who is sponsoring clinical trial NCT02135965?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02135965 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Human Milk Oligosaccharide-Based Synbiotic Supplement for Intestinal Microbiota Dysbiosis
RECRUITING · Early Phase 1
-
Chronic Transcutaneous Stimulation to Promote Motor Function and Recovery in Individuals With Paralysis or Paresis
RECRUITING · Early Phase 1
-
Sustained Release Oral Formulation for Treatment of Parkinson's Disease
RECRUITING · Early Phase 1
-
Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects
COMPLETED · Early Phase 1
-
Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein
COMPLETED · Early Phase 1
-
Adaptive Optics Retinal Imaging
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.